SLC25A12

Across TCGA pan-cancer cohorts, SLC25A12 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SLC25A12 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SLC25A12 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC25A12 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where SLC25A12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.301	0.534	.003	24	view →
CCRCC	DFS	Tertile	All	1.000	0.599	.003	7	view →
LUAD	DFS	Median	All	0.962	0.840	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SLC25A12–PDAC (DFS)

Open the PDAC breakdown →